644964-99-8

Upstream product

• 2304-98-5 N₅-[imino(nitroamino)methyl]-N₂-[(phenylmethoxy)carbonyl]-L-ornithine 
• 42891-37-2 6-amino-6-deoxy-α,α-D-trehalose 
• 43060-53-3 6-azido-6-deoxy-α-D-glucopyranosyl-(1→1)-α-D-glucopyranoside 
• 42891-35-0 2,3,4,2',3',4',6'-hepta-O-acetyl-6-bromo-6-deoxy-α,α-trehalose 
• 35014-70-1 2,3,4-tri-O-acetyl-6-azido-6-deoxy-α-D-glucopyranosyl-(1→1)-2,3,4,6-tetra-O-acetyl-α-D-glucopyranoside 

Relevant academic research and scientific papers

Design and synthesis of guanidinoglycosides directed against the TAR RNA of HIV-1

Replication of human immunodeficiency virus type 1 (HIV-1) requires specific interactions of the Tat protein with the transactivation responsive region (TAR) RNA. Tat-TAR RNA Interaction is mediated by a short arginine-rich domain of the protein. Disruption of this interaction could, in theory, create a state of complete viral latency. Here, four novel 6-amino-6-deoxytrehalose guanidinoglycoside derivatives (10 and 13-15) as target molecules have been designed to bind to TAR RNA for blocking the interaction of Tat-TAR RNA. They were obtained by coupling 6-amino-6-deoxy-α,α-trehalose (6) with the protected amino acids, deprotection by catalytic hydrogenation, followed by guanidinylated with S-methylisothiourea sulfate. Their abilities to inhibit Tat-TAR RNA interaction were determined by a Tat-dependent HIV-1 long terminal repeats (LTR)-driven chloramphenicol acetyltransferase (CAT) assays.